Compare
SI-BONE, Inc. vs Lemaitre Vascular Inc vs NeuroPace Inc vs Embecta Corp.
| Latest fiscal year | SI-BONE, Inc. SIBN | Lemaitre Vascular Inc LMAT | NeuroPace Inc NPCE | Embecta Corp. EMBC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $200.93M | $249.60M | $99.99M | $1.08B |
| Revenue growth (YoY) | +20.2% | +13.5% | +25.1% | -3.8% |
| Gross margin | 79.6% | 71.5% | 77.2% | 62.6% |
| Operating margin | -11.1% | 27.2% | -16.3% | 22.4% |
| Net margin | -9.4% | 23.1% | -21.5% | 8.8% |
| Net income | -$18.90M | $57.73M | -$21.46M | $95.40M |
| EPS (Diluted) | -$0.44 | $2.52 | -$0.66 | $1.62 |
| Operating cash flow | -$675.0K | $81.25M | -$11.01M | $191.70M |
| Free cash flow | -$9.09M | $74.47M | -$11.34M | $182.40M |
| Cash & equivalents | $42.24M | $28.24M | $21.69M | $225.50M |
| Total assets | $238.56M | $615.69M | $105.56M | $1.09B |
| Total liabilities | $61.02M | $222.17M | $86.53M | n/a |
| Shareholders' equity | $177.53M | $393.52M | $19.03M | -$650.60M |
| Return on year-end equity | -10.6% | 14.7% | -112.8% | n/a |
| Shares outstanding | 43.65M | 22.77M | 33.57M | 58.50M |
Revenue, most recent five fiscal years
| Fiscal year | SI-BONE, Inc. | Lemaitre Vascular Inc | NeuroPace Inc | Embecta Corp. |
|---|---|---|---|---|
| Latest | $200.93M Ended 2025-12-31 | $249.60M Ended 2025-12-31 | $99.99M Ended 2025-12-31 | $1.08B Ended 2025-09-30 |
| 1 year earlier | $167.18M Ended 2024-12-31 | $219.86M Ended 2024-12-31 | $79.91M Ended 2024-12-31 | $1.12B Ended 2024-09-30 |
| 2 years earlier | $138.89M Ended 2023-12-31 | $193.48M Ended 2023-12-31 | $65.42M Ended 2023-12-31 | $1.12B Ended 2023-09-30 |
| 3 years earlier | $106.41M Ended 2022-12-31 | $161.65M Ended 2022-12-31 | $45.52M Ended 2022-12-31 | $1.13B Ended 2022-09-30 |
| 4 years earlier | $90.15M Ended 2021-12-31 | $154.42M Ended 2021-12-31 | $45.18M Ended 2021-12-31 | $1.17B Ended 2021-09-30 |